ZNRF2 Activators
ZNRF2 Activators encompass a diverse array of chemical compounds that indirectly enhance the functional activity of ZNRF2-a ubiquitin ligase-through various signaling pathways and molecular mechanisms. Phosphatidylinositol 3,4,5-trisphosphate (PIP3) plays a pivotal role by activating the PI3K/Akt pathway, thereby reducing ZNRF2-mediated degradation of pathway components and enhancing ZNRF2's ubiquitination processes. Similarly, the use of a Ubiquitin Activating Enzyme E1 Inhibitor escalates the ubiquitin pool, thus potentially augmenting ZNRF2's ligase activity. Proteasome inhibitor MG132, by inhibiting the breakdown of ubiquitinated proteins, indirectly causes an accumulation of ZNRF2 substrates, reinforcing ZNRF2's role in protein turnover. Antioxidant Pyrrolidine Dithiocarbamate (PDTC) suppresses NF-κB activation, possibly necessitating greater reliance on ZNRF2 pathways for cellular functions. Forskolin and Prostaglandin E2 (PGE2) engage adenylyl cyclase and G protein-coupled receptors, respectively, to stimulate cAMP and activate PKA, which may phosphorylate and thus potentiate ZNRF2 activity.
Additionally, Okadaic Acid's prevention of protein dephosphorylation can alter the phosphorylation state of proteins within ZNRF2's operational pathways, which may inadvertently boost ZNRF2's ubiquitination efficiency. The release of nitric oxide by S-Nitroso-N-acetylpenicillamine (SNAP) can induce S-nitrosylation of proteins, possibly affecting ZNRF2 or its substrates and thus modulating its activity. Zinc Pyrithione boosts intracellular zinc levels, which could stabilize ZNRF2's structure and enhance its ubiquitin ligase function. Inhibition of GSK-3 by Lithium Chloride might increase substrate availability for ZNRF2 through stabilization of proteins in pathways like Wnt. Tunicamycin triggers the unfolded protein response (UPR), which could inadvertently activate ZNRF2 as part of the cellular response to misfolded proteins. Lastly, Thapsigargin's elevation of cytosolic calcium might activate calcium-dependent enzymes and pathways, thereby potentially influencing ZNRF2's activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
By inhibiting the E1 activating enzyme, this compound would theoretically increase the availability of free ubiquitin. This could lead to an upregulation of ZNRF2's activity due to more substrate availability for its E3 ligase function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. By preventing the degradation of ubiquitinated proteins, MG132 could lead to the accumulation of ZNRF2 substrates, indirectly increasing the functional activity of ZNRF2 as an E3 ubiquitin ligase. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $33.00 $64.00 | 11 | |
PDTC is an antioxidant that inhibits NF-κB activation. ZNRF2 has been shown to regulate NF-κB activity indirectly. By inhibiting NF-κB, PDTC may increase the cellular reliance on ZNRF2-mediated pathways for cell survival. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cAMP levels, which subsequently activates PKA. PKA can phosphorylate ZNRF2, potentially enhancing its stability or activity as an E3 ubiquitin ligase. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A. Inhibition of these phosphatases can lead to increased phosphorylation of proteins involved in the same pathways as ZNRF2, potentially enhancing its activity by altering substrate availability or recognition. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 works through G protein-coupled receptors to activate cyclic AMP pathways. The increase in cAMP can enhance the PKA-mediated phosphorylation of proteins, which may include ZNRF2 or its substrates, thereby potentially enhancing the activity of ZNRF2. | ||||||
(±)-S-Nitroso-N-acetylpenicillamine | 79032-48-7 | sc-200319B sc-200319 sc-200319A | 10 mg 20 mg 100 mg | $74.00 $114.00 $374.00 | 18 | |
SNAP releases nitric oxide, which can lead to S-nitrosylation of proteins. The modification of cysteine residues by S-nitrosylation within ZNRF2 or its interacting partners could affect their activity, potentially enhancing ZNRF2 function. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc Pyrithione can increase intracellular zinc levels, which may be necessary for the proper function of zinc finger proteins like ZNRF2. Enhanced zinc levels could stabilize the structure of ZNRF2, thereby potentially increasing its activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3, which is involved in various signaling pathways including Wnt. Inhibition of GSK-3 could stabilize proteins in these pathways, potentially increasing the number of substrates available for ZNRF2-mediated ubiquitination. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation. This stress on the ER can lead to unfolded protein response (UPR) activation. ZNRF2 could be indirectly activated as part of the cellular response to enhance the degradation of misfolded proteins. | ||||||